Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection (PREPCOV)

Inclusion Criteria:

Group with hydroxychloroquine treatment (HC +):

• LED/SG diagnosed
• Treatment with Hydroxy-Chloroquine in the 3 months before and during the outbreak at COVID 19, at least in December 2019. Patients may have treatment with Azathioprine or Methotrexate in combination with Hydroxy-Chloroquine.
• COVID19 diagnostic questionnaire and available serology result.

Group without hydroxychloroquine treatment (HC-) :

• No Hydroxy-Chloroquine intake for more than 12 months

  --> HC- without an immunosuppressant

• Viral hepatitis C cured for more than 12 months or primitive bile cholangitis (CBP) whose diagnosis is based on international criteria.
• Non-significant liver fibrosis assessed either by historical histology or by fibroscan with non-significant liver fibrosis Metavir - F3 (at last available examination)
• No Hydroxy-Chloroquine, Azathioprine or Methotrexate or other immunosuppressants have been taken for more than 12 months.

• COVID19 diagnostic questionnaire and COVID19 serology result available.

  -->HC- with an immunosuppressant

• Diagnosis of LED/SG according to the CAB criteria revised in 1997 or autoimmune hepatitis according to the international criteria validated in 2008.
• Patients treated with Azathioprine (autoimmune hepatitis or LED/SGJ)) or Methotrexate (LED/SGJ) for at least three months before the start of the pandemic at COVID 19, at least since December 2019.
• COVID19 diagnostic questionnaire and available serology result.

Exclusion Criteria:

• Anti-CD20 or Cyclophosphamide taken during the six months prior to the completion of the COVID 19 serology.
• Refusal of a blood test for antibodies to COVID-19.
• Protected adults
• Pregnant or breastfeeding women.
• Lack of health insurance coverage